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Sepsis is a major cause of death for hospitalized patients and is characterized by massive 
overreaction of immune responses to invading pathogens which is mediated by cyto-
kines. For decades, there has been no effective treatment for sepsis. Sialic acid-binding, 
Ig-like lectin-9 (Siglec-9), is an immunomodulatory receptor expressed primarily on 
hematopoietic cells which is involved in various aspects of inflammatory responses and 
is a potential target for treatment of sepsis. The aim of the present study was to develop 
a human anti-Siglec-9 Fab fragment, which was named hS9-Fab03 and investigate its 
immune activity in human macrophages. We began by constructing the hS9-Fab03 
prokaryotic expression vector from human antibody library and phage display. Then, 
we utilized a multitude of assays, including SDS-PAGE, Western blotting, ELISA, affinity, 
and kinetics assay to evaluate the binding affinity and specificity of hS9-Fab03. Results 
demonstrated that hS9-Fab03 specifically bind to Siglec-9 antigen with high affinity, and 
pretreatment with hS9-Fab03 could attenuate lipopolysaccharide (LPS)-induced TNF-
α, IL-6, IL-1β, IL-8, and IFN-β production in human PBMC-derived macrophages, but 
slightly increased IL-10 production in an early time point. We also observed similar results 
in human THP-1-differentiated macrophages. Collectively, we prepared the hS9-Fab03 
with efficient activity for blocking LPS-induced pro-inflammatory cytokines production in 
human macrophages. These results indicated that ligation of Siglec-9 with hS9-Fab03 
might be a novel anti-inflammatory therapeutic strategy for sepsis.
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inTrODUcTiOn
Sepsis is a leading cause of mortality in intensive care units; recent statistics have indicated the 
occurrence about 19 million cases worldwide per year (1). Current treatments for sepsis are typically 
supportive and often ineffective, despite the fact that the number of deaths per year is around eight 
million (2). Moreover, more than 30% of survivors suffer from long-term functional disabilities 
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and persistent critical illness (3). Lethality caused by sepsis 
arises from a massive hyperinflammatory immune response to 
pathogens, such as Gram-negative organisms, Gram-positive 
organisms, and fungi (4). The uncontrolled pro-inflammatory 
responses that lead to organ dysfunction in sepsis are primar-
ily initiated by the toll-like receptors (TLRs), which recognize 
pathogen-associated molecular patterns (PAMPs), such as bacte-
rial lipoproteins, lipopolysaccharide (LPS), and non-methylated 
CpG DNA (5). TLR4 activation results in the synthesis and 
release of pro-inflammatory cytokines, such as TNF-α, IL-6, 
IL-8, and IFN-β, which act locally but are released systemically, 
initiating the cytokines storm that damage vital tissues (6, 7). 
Our recent studies indicated that anti-TLR4 Fab fragment could 
reduce the inflammatory responses by inhibiting LPS-induced 
TLR4 signaling pathway in mouse primary macrophages and 
human THP-1-differentiated macrophages (8, 9). Therefore, it is 
intriguing that macrophages and inflammatory cytokines could 
be potential therapeutic targets in patients with sepsis.
Sialic acid-binding immunoglobulin-type lectins (Siglecs) 
are a family of sialic acid-binding immunoglobulin-like lectins 
that are differentially presented on the surface of hematopoietic 
cells, which exert immunomodulatory functions via glycans or 
glycoproteins recognition during immune responses (10, 11). 
Siglecs can be categorized into two groups. CD169, CD22, MAG, 
and Siglec-15 are conserved across mammals. In comparison, 
the CD33-related Siglecs are variable across mammals (12). 
It has been suggested that CD33-related Siglecs may serve as a 
negative regulator for immunocytes behavior, such as inhibition 
of cellular activation, induction of apoptosis, and suppression 
of pro-inflammatory cytokines production (13). All of CD33-
related Siglecs may transduct through their immunorecep-
tor tyrosine-based inhibitory motifs (ITIMs) located in the 
cytoplasmic region (except for Siglec-14), which are associated 
with SHP-1 and/or SHP-2 (14, 15). Siglec-9, as a member of 
the CD33-related Siglecs, is predominantly presented on neu-
trophils, monocytes, macrophages, and dendritic cells (DCs), 
whose mouse ortholog Siglec-E are expressed on neutrophils, 
monocytes, and conventional dendritic cells (16, 17). Siglec-9 
has a characteristic N-terminal, Ig-like, V-type domain which 
could mediate its binding to sialic acid moiety of glycans and 
glycoproteins, a single transmembrane region, and a cytoplasmic 
tail that contain an ITIM and SLAM-like motif (18, 19). It is well 
established that ligation of the Siglec-9 induces phosphorylation 
of the tyrosine within the ITIM and recruit tyrosine phosphatase 
SHP-1 and SHP-2, then exerts its inhibition during innate and 
acquired immunity (20).
The cross talks between Siglecs family and TLRs are under 
intense investigation. Recently, Siglecs expressed on neutrophils, 
macrophages, and DCs could regulate TLRs-induced cytokines 
production through small RNA interference or in vitro ligation 
with Siglecs-specific antibodies. Results showed that Siglec-G 
could not regulate responses to microbial products directly, but 
instead it might interact with the receptor CD24 in cis to inhibit 
DC-initiated inflammatory reactions (21). Chen et  al. showed 
that Siglec-G expression could be upregulated on macrophages 
after infection by vesicular stomatitis virus (VSV) or Sendai virus, 
which lead to the degradation of retinoic acid-inducible gene I 
and inhibition of the IFN-β production (22). Furthermore, recent 
results suggest that Siglec-9 inhibits the production of TNF-α 
while promotes the secretion of the IL-10 upon stimulation with 
LPS in macrophages, but the precise mechanism of Siglec-9-
influenced LPS signaling pathway is still unknown (23).
Thus, we prepared the Fab fragments of human anti-Siglec-9 
monoclonal antibody (hS9-Fab03) from human antibody library 
and phage display and examined whether treatment of hS9-Fab03 
could regulate immune responses upon stimulation by LPS in 
human macrophages. In this study, we report that hS9-Fab03 
not only attenuates LPS-induced TNF-α, IL-6, IL-1β, IL-8, and 
IFN-β production in human PBMC-derived macrophages but 
also slightly increases IL-10 production in an early time point.
MaTerials anD MeThODs
cells and reagents
The THP-1 cells were acquired from the cell bank of Shanghai 
Institute of Biochemistry and Biology (Chinese Academy of 
Sciences, Shanghai, China). RPMI-1640 medium and fetal bovine 
serum (FBS) were obtained from Gibco (Carlsbad, CA, USA). 
LPS (O111:B4), PMA, Ficoll-Paque Plus, and commercial anti-
Siglec-9 antibody were obtained from Sigma-Aldrich (St. Louis, 
MO, USA), Abs specific to GAPDH, total p38, phosphorylated 
JNK1/2, p38, p65, and IRF-3 were purchased from Cell Signaling 
Technology (Danvers, MA, USA). His-trap Lambda Fab Select 
column was obtained from GE Healthcare (Piscataway, NJ, USA). 
Anthrax chimeric Fab antibody was prepared in our lab.
cell culture and Differentiation
THP-1 cells were cultured in RPMI-1640 supplied with 10% FBS, 
1% penicillin, and streptomycin in a 5%-CO2 humidified incuba-
tor at 37°C. The THP-1 cells were stimulated with 10 nM PMA for 
48 h, then THP-1-derived macrophages were differentiated. The 
PBMC-derived macrophages were cultured and differentiated as 
previously reported (24). Briefly, human PBMCs were separated 
by centrifugation on Ficoll-Paque Plus and purified by CD14-
positive cells isolation kit (Miltenyi Biotec, CA, USA). The purified 
cells were differentiated in complete RPMI-1640 supplied with 
M-CSF (10 ng/ml) (BD Biosciences, CA, USA) for 6 days. Donor 
blood samples were randomly collected in the Jiangsu Province 
Blood Center. The study was approved by Ethical Committee of 
Anhui Medical University Affiliated with Bayi Clinical College 
and all participants signed an informed consent form when they 
filled the questionnaire.
Phage library and helper Phage
A human naive Fab phage library for Siglec-9 selection was gener-
ated as previously described (25). Before the first round panning, 
the phage library was titrated and 1 ×  1013 phage clones were 
collected for panning.
Phage elisa
Single phage clone from the E. coli XL1-Blue infected by the 
seventh round of eluted phage was randomly picked up and 
FigUre 1 | Preparation of the hs9-Fab03.  
 (Continued)
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grown in 1 ml super broth (SB) medium containing 100 µg/ml 
ampicillin and 1% glucose. VCSM13 helper phage (1 × 109) was 
added to each vial. Then, 50  µl of supernatant from each vial 
was added to each well of 96-well plate, which was pre-coated 
with 100  ng extracellular domain of Siglec-9 antigen. After 
incubation for 2 hours and washing for three times, 50  µl of 
(a) The heavy chain PCR products of positive clone. Lane 1, VH; Lane 2, CH; Lane 3, VH combined with CH; Lane M, DNA maker. (B) The light chain PCR products of 
positive clone. Lane 1, VL; Lane 2, CL; Lane 3, VL combined with CL; Lane M, DNA maker. (c) The construction of pETDuet-hSiglec-9 Fab03. Lane 1, the plasmid 
without restriction endonuclease digestion; Lane 2, the plasmid was double digested with NcoI and XhoI; Lane 3, NcoI and HindIII were used for double digesting 
the plasmid; Lane 4, EcoRV and XhoI were used for double digesting the plasmid; Lane M, DNA marker. Coomassie blue staining (D) and Western blotting  
(e) detected the expression of the recombinant vector. Lane 1, whole lysate of untransfected E. coli BL21, as a negative control; Lane 2, whole lysate of  
pETDuet-hSiglec-9 Fab03-transfected E. coli; Lane 3, supernatant of sonicated lysate of pETDuet-hSiglec-9 Fab03-transfected E. coli; Lane 4, sediment of 
sonicated lysate of pETDuet-hSiglec-9 Fab03-transfected E. coli; Lane M, protein marker. All strains were induced by IPTG overnight. Coomassie blue staining  
(F) and Western blotting (g) detected the purified Fab fragments. Lane 1, supernatant of sonicated lysate of pETDuet-hSiglec-9 Fab03-transfected E. coli induced 
by IPTG overnight; lane M, protein marker. (h) Coomassie blue staining showed that the hS9-Fab03 was expressed, and the heavy chain Fd and light chain L were 
linked together. (i) horseradish-peroxidase-conjugated goat anti-human antibody (Fab specific) was used to detect the heavy chain Fd, and light chain L of the 
hS9-Fab03 was expressed and separated in Western blotting. Coomassie blue staining (J) and Western blotting (K) detected the efficiency of hS9-Fab03. Lane 1, 
supernatant of sonicated lysate of the pETDuet-hSiglec-9 Fab03-transfected E. coli was purified by the His-trap Lambda Fab Select column; lane 2, whole lysate of 
pETDuet-hSiglec-9 Fab03-transfected E. coli induced by IPTG overnight; lane M, protein marker.
FigUre 1 | continued
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horseradish-peroxidase (HRP)-conjugated anti-M13 antibody 
solution was added to each well. Finally, the highest absorbance 
of the positive clones was selected for further evaluation.
construction of the hs9-Fab03  
expression Vector
Total RNA was extracted from positive cells by the TRIzol reagent 
(Invitrogen, CA, USA) and converted to complementary DNA 
(cDNA) by the Prime Script RT Master Mix kit (TaKaRa, Shiga, 
Japan) according to the manufacturer’s protocol. The variable 
regions of the heavy (VH) chain and the light (VL) chain were 
amplified with primers shown in Table S1 in Supplementary 
Material. The conserved regions of the heavy (CH1) and light (CL) 
chains were provided by the Barbas laboratory (Scripps Research 
Institute, USA). The VH and VL were amplified and cloned into 
pMD-18T vector, respectively. The heavy chain Fd and the light 
chain L were amplified with HF1, HR2, and LL1, LR2, respec-
tively. The Fd and L were cloned into pETDuet-1 at NcoI/HindIII 
and EcoRV/XhoI, respectively.
Western Blotting
The expression of hS9-Fab03 in E. coli BL21 was detected by 
Western blotting as previously described (26). The concentrations 
of proteins were determined by bicinchoninic acid protein assay kit 
(Thermo, Waltham, MA, USA). The proteins from bacteria lysate 
were dissociated by 12% SDS-PAGE and then transferred onto 
nitrocellulose membrane (Bio-Rad, CA, USA). The membrane 
was blocked by 5% non-fat milk in TBST for 1 h at room tempera-
ture, which was then incubated with HRP-conjugated goat anti-
human antibody (Fab specific) (Santa Cruz Biotechnology, CA, 
USA). The THP-1-derived macrophages (1 × 106 cells/well) were 
pretreated with the hS9-Fab03 (5 µg/ml) for 2 h and stimulated 
with LPS (1 µg/ml) for 0, 15, 30, and 60 min. The phosphorylation 
level of NF-κB/MAPKs/IRF-3 signaling pathway were detected 
and analyzed.
Fluorescence-activated  
cell sorting (Facs)
The THP-1-derived macrophages were treated with the hS9-
Fab03 for 2 h; the cells were then incubated with goat anti-human 
IgG (Fab specific)-FITC antibody (Sigma-Aldrich, MO, USA) at 
37°C for 1 h. The cells were analyzed by LSRII flow cytometer (BD 
Biosciences, CA, USA).
elisa
TNF-α, IL-1β, IL-6, IL-10, and IL-8 in supernatants were deter-
mined with ELISA kits (R&D Systems, MN, USA).
surface Plasmon resonance (sPr) 
analysis of the hs9-Fab03
We optimized the coupling condition based on the isoelectric 
point of the Siglec-9 protein, and sodium acetate was chosen as 
the dilution buffer for Biacore X100 SPR system (GE, Sweden). 
The Siglec-9 protein was diluted to 30 µg/ml and coupled to the 
CM5 chip. The coupling level was set at 1,500 RU, the injection 
time was set to 180 s, the dissociation time was set to 15 min, and 
50 mM Gly-HCl (pH = 1.7) was used as the regeneration buffer. 
Finally, the Siglec-9 protein was treated with serial concentrations 
of hS9-Fab03 to detected the antibodies’ binding affinity.
real Time Q-Pcr
The total RNA was extracted using RNAfast200 (Feijie, Shanghai, 
China) following the manufacturer’s instructions. A quantity of 
0.5 µg total RNA was used in a 10-µl reverse-transcription reac-
tion using the PrimeScript RT Master Mix kit, then the cDNA 
was diluted into 40 µl as template for real time Q-PCR. Q-PCR 
analysis was performed using LightCycler (Roche Diagnostic, 
IN, USA). The primers used for human GAPDH, TNF-α, IL-6, 
IL-1β, IL-8, IL-10, and IFN-β were as described previously (27). 
Data were normalized by the level of GAPDH expression in each 
sample.
statistical analysis
The significance of differences was analyzed by Student’s t-test and 
Mean ± SD was calculated, with a value of p < 0.05 considered to 
be statistically significant.
resUlTs
Preparation of human anti-siglec-9  
Fab Fragments
Generally, with seven rounds of affinity panning, 50 single 
phages were selected and analyzed by phage ELISA. While 
FigUre 2 | The hs9-Fab03 specifically binds the siglec-9 antigen. (a) 96-well plates were pre-coated with recombinant human Siglec-9, 10 µg/ml. Serial 
concentrations of the hS9-Fab03 were used as the primary antibody. Horseradish-peroxidase-conjugated goat anti-human antibody (Fab specific) was used as the 
secondary antibody. Commercial anti-Siglec-9 antibodies were used as positive control (Ctrl). The absorbance was read at 450 nm after color development. (B) The 
hS9-Fab03 was diluted with buffer solution to 30 µg/ml and then treated with a running buffer containing different concentrations of hS9-Fab03. Results were 
analyzed using the Biacore X100 software. (c) PMA-stimulated THP-1-differentiated macrophages were treated or untreated with hS9-Fab03 at 4°C for 1 h, Goat 
anti-human IgG (Fab specific)-FITC antibody was incubated with macrophages for 1 h in the dark at 37°C. The cells were determined by fluorescence-activated cell 
sorting. Experiments were repeated in triplicate. Data are shown as mean ± SD (n = 3, N.S., not significant, *p < 0.05, **p < 0.01, ***p < 0.001 compared to control).
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FigUre 3 | The hs9-Fab03 inhibits lipopolysaccharide (lPs)-induced inflammatory cytokines production in ThP-1-derived macrophages.  
PMA-stimulated THP-1-differentiated macrophages in 24 wells were pre-incubated with 5 µg/ml hS9-Fab03 for 2 h, then stimulated with 1 µg/ml LPS. Anthrax 
chimeric Fab antibody was used as the negative control. The mRNA expression levels of IFN-β (a), TNF-α (B), IL-6 (c), IL-1β (D), IL-10 (e), and IL-8 (F) were 
detected by Q-PCR. Experiments were performed in triplicate. Data are shown as mean ± SD (n = 3, N.S., not significant, *p < 0.05, **p < 0.01, ***p < 0.001 
compared to negative control).
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the positive and negative ratio was exceeded 4, the phage 
was considered positive. Ten positive phages were possessed, 
amplified, and confirmed by sequencing. After examining the 
sequence in VBASE2 database, the light chain was classified 
as lambda chain. Consequently, we amplified the VL and CL 
of selected positive clones with universe primers, which were 
designed by our lab as previously reported (28). The length 
of VH and CH1 were close to 400  bp (Figure  1A). Similarly, 
the length of VL and CL were approximately 400 and 350 bp, 
respectively (Figure 1B). Then, the heavy chain Fd and light 
chain L were spliced by overlap extension-polymerase chain 
reaction (29), which were approaching to 800 and 750  bp, 
FigUre 4 | inhibitory effect of hs9-Fab03 on cytokine expression in cell culture supernatant of lipopolysaccharide (lPs)-stimulated ThP-1-
differentiated macrophages. THP-1-differentiated macrophages were pre-incubated with 5 µg/ml hS9-Fab03 for 2 h, then stimulated with 1 µg/ml LPS. Anthrax 
chimeric Fab antibody was used as the negative control. The production of IFN-β (a), TNF-α (B), IL-1β (c), IL-6 (D), IL-8 (e), and IL-10 (F) in human THP-1-
differentiated macrophage culture supernatant was determined by ELISA analysis. Data are shown as mean ± SD (n = 3, N.S., not significant, *p < 0.05, **p < 0.01, 
***p < 0.001 compared to negative control).
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respectively. Finally, the Fd and L fragments were inserted into 
the prokaryotic expression plasmid pETDuet-1 sequentially 
affirmed by digestion and sequencing (Figure 1C). Therefore, 
the prokaryotic expression vector of human anti-Siglec-9 Fab 
fragments (pETDuet-hSiglec-9 Fab03) had been constructed 
successfully.
The vector of pETDuet-hSiglec-9 Fab03 was transformed into 
E. coli BL21 and induced with 1 mmol/l IPTG overnight at 16 or 
37°C, the recombinant E. coli was preferred to express more Fab 
fragments (data not shown). Then the lysate of the recombinant 
E. coli was examined by SDS-PAGE gel with Coomassie brilliant 
blue staining, the bands of Fd and L were overlapped due to their 
similar DNA length (Figure 1D). To determine whether the Fab 
fragments were expressed in the inclusion body, western blotting 
was utilized. We observed that the recombinant proteins were 
primarily secreted in the component of ultrasonic supernatant 
but not that of sediment (Figure 1E). After purification, the Fab 
antibodies were presented at 27 kDa (Figures 1F,G). Compared 
with SDS-PAGE electrophoresis, Native-PAGE could reduce the 
possibility of protein denaturalization. As shown in Figures 1H,I, 
results showed that two obvious bands were at 27 and 55 kDa, 
respectively.
Considered to light chain of the recombinant protein was 
lambda chain; the purification of the human anti-Siglec-9 Fab 
fragments (hS9-Fab03) was achieved by His-trap Lambda Fab 
Select column. The purification efficiency of target proteins was 
above 95% with the concentration of hS9-Fab03 up to 1.0 mg/
ml (Figures  1J,K). Collectively, the hS9-Fab03 was success-
fully expressed at high concentration to explore its affinity and 
immune activity.
The hs9-Fab03 specifically Binds siglec-9
To examine whether the hS9-Fab03 could specifically bind to 
Siglec-9 antigen, the ELISA assay was carried out with different 
concentration of hS9-Fab03, and the commercial anti-Siglec-9 
antibody was used as positive control. Next, the concentration of 
hS9-Fab03 was diluted from 0.5 to 0.07 mg/ml. The absorbance 
FigUre 5 | The hs9-Fab03 inhibits lipopolysaccharide (lPs)-induced inflammatory cytokines production in human PBMc-derived macrophages. 
Human PBMC-differentiated macrophages in 24 wells were pre-incubated with 5 µg/ml hS9-Fab03 for 2 h, then stimulated with 1 µg/ml LPS. Anthrax chimeric Fab 
antibody was used as the negative control. The mRNA expression levels of IFN-β (a), TNF-α (B), IL-1β (c), IL-6 (D), IL-8 (e), and IL-10 (F) were detected by 
Q-PCR. Experiments were performed in triplicate. Data are shown as mean ± SD (n = 3, N.S., not significant, *p < 0.05, **p < 0.01, ***p < 0.001 compared to 
negative control).
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value at 450 nm was from 1.174 to 0.216 (Figure 2A). Finally, the 
ELISA results showed that the hS9-Fab03 could particularly bind 
to Siglec-9 antigen in a dose-dependent manner, which was as 
good as the commercial antibody.
Aiming to characterize the binding capacity of hS9-Fab03, we 
further calculated the affinity constant using the following for-
mula: affinity constant (KD) = dissociation constant (Kd) ÷ bind-
ing constant (Ka) (30). Results from the Biacore X100 SPR 
analysis demonstrated that the affinity constant of hS9-Fab03 was 
6.58 × 10−7 (Figure 2B). Taken together, these results indicated 
that hS9-Fab03 could effectively bind to Siglec-9 protein.
The binding ability of hS9-Fab03 was further analyzed 
with Flow cytometry in Siglec-9-positive THP-1-derived 
macrophages. Our results revealed that the population of 
hS9-Fab03-treated THP-1 cells was divided from unbinding 
cells, whereas no apparent difference was detected in blank 
and FITC antibody-treated cells (Figure 2C). This implied that 
hS9-Fab03 could effectively bind to Siglec-9 expressed on the 
cells’ surface.
The hs9-Fab03 inhibits lPs-induced 
inflammatory cytokines Production  
In Vitro
Human macrophages have been widely used for studying TLRs 
signaling (31). To investigate the role of Siglec-9 during LPS-
initiated inflammatory responses, we determined the efficient 
pre-incubated time and optimized concentrations of hS9-Fab03 
and LPS. When the concentration of hS9-Fab03 range from 0.1 
to 5 µg/ml, the inhibition efficiency of IFN-β and TNF-α mRNA 
levels were increased in a concentration-dependent manner 
(Figures S1A,B in Supplementary Material). Then, when the 
concentration of hS9-Fab03 was at 5  µg/ml, the pre-incubated 
time of hS9-Fab03 was ranging from 30 min to 4 h, the inhibition 
efficiency of IFN-β and TNF-α mRNA levels was better at 2  h 
(Figures S1C,D in Supplementary Material). Furthermore, treat-
ment with 5 µg/ml of hS9-Fab03 reduced LPS-initiated inflamma-
tory responses by approximately 85% of IFN-β expression and by 
approximately 70% of TNF-α expression than without antibody 
FigUre 6 | inhibitory effect of hs9-Fab03 on cytokine expression in cell culture supernatant of lipopolysaccharide (lPs)-stimulated human 
PBMc-differentiated macrophages. Human PBMC-differentiated macrophages were pre-incubated with 5 µg/ml hS9-Fab03 for 2 h, then stimulated with 1 µg/
ml LPS. Anthrax chimeric Fab antibody was used as the negative control. The production of IFN-β (a), TNF-α (B), IL-1β (c), IL-6 (D), IL-8 (e), and IL-10 (F) in 
human PBMC-differentiated macrophage culture supernatant were determined by ELISA analysis. Data are shown as mean ± SD (n = 3, N.S., not significant, 
*p < 0.05, **p < 0.01, ***p < 0.001 compared to negative control).
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treatment (Figures S1E,F in Supplementary Material). Finally, we 
conducted the following experiments with pre-incubation time 
at 2 h and the concentration of hS9-Fab03 and LPS at 5 and 1 µg/
ml, respectively.
Next, we investigated whether hS9-Fab03 ligation could 
regulate the expression of pro-inflammatory cytokines in human 
macrophages. The THP-1-differentiated macrophages were pre-
treated with the hS9-Fab03 and stimulated with LPS for different 
time. The mRNAs were collected to evaluate the expression of 
pro-inflammatory cytokines. We found that hS9-Fab03 could 
obviously inhibit LPS-initiated production of pro-inflammatory 
cytokines, such as TNF-α, IL-6, and IFN-β, no effect on the 
expression of IL-1β, IL-8, and IL-10 in THP-1-differentiated 
macrophages (Figures 3 and 4). Similarly, we observed that pre-
incubation of hS9-Fab03 could also suppress the TNF-α, IL-6, 
IL-1β, IL-8, and IFN-β expression of pro-inflammatory in human 
PBMC-derived macrophages stimulated with LPS, but slightly 
increased IL-10 production in an early time point compared 
to group with LPS only (Figures  5 and 6). We also incubated 
different concentrations of hS9-Fab03 macrophages and found 
that hS9-Fab03 could effectively block LPS-induced TNF-α and 
IFN-β expression in a dose-dependent manner (Figures S1A,B in 
Supplementary Material). Thus, the results implied that the hS9-
Fab03 could inhibit LPS-induced pro-inflammatory cytokines 
production in human macrophages.
suppression of lPs-initiated Tlr4 
signaling by the hs9-Fab03
To investigate the inhibitory effects of the hS9-Fab03 on TLR4 
signaling transduction induced by LPS ligation, we detected the 
phosphorylation levels of NF-κB, MAPKs, and IRF-3 signal-
ing pathways. As shown in Figure  7, LPS ligation significantly 
increased the phosphorylation level of these proteins in THP-
1-differentiated macrophages, but the phosphorylation level of 
p65, p38, JNK1/2, and IRF-3 was suppressed when pretreated 
with 5 µg/ml of the hS9-Fab03. Thus, these results demonstrated 
that the hS9-Fab03 could suppress LPS-triggered TLR4 signaling 
transduction.
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DiscUssiOn
In this study, we utilized the human Fab phage library to construct 
an active anti-Siglec-9 antibody Fab fragments (hS9-Fab03) 
that could recognize recombinant Siglec-9 protein. The screen-
ing strategy was applied by the repeated panning with coated 
recombinant Siglec-9 protein in microtiter plates to assure the 
efficiency of specific Siglec-9 binding phage. After seven rounds 
of screening, 10 of 50 selected candidate phage clones displayed 
strong positive signal, and ELISA results indicated that these 
clones possess the specifically binding ability. After this, the 
prokaryotic expression vector pETDuet-hSiglec-9 Fab03 was 
successfully constructed. Our reliable approach ensured that the 
two different chains are comparatively expressed and efficiently 
dimerized into active hS9-Fab03, which ensured the production 
of stable antibody fragments (32). Series of western blotting and 
SDS-PAGE with Coomassie brilliant blue staining confirmed the 
efficient expression and purification of hS9-Fab03. Moreover, 
FACS confirmed the specifically binding ability of hS9-Fab03 to 
Siglec-9 protein expressed on the surface of THP-1-differentiated 
macrophages. Thus, these results demonstrated that the antibody 
engineering process couldn’t change the specificity of the human 
anti-Siglec-9 Fab fragments.
Sepsis is a systemic infection characterized by the release of 
pro-inflammatory cytokines inducing systemic immune activa-
tion and coagulation activation and causing severe sepsis and 
septic shock (33). TLRs are fundamental for the initiation of the 
protective pro-inflammatory responses, which served as the first 
line of host defense against infection (34, 35). The uncontrolled 
pro-inflammatory cytokine production is critically involved in a 
variety of pathologies, such as sepsis and autoimmune diseases 
(36). TLR4 were mainly responded to PAMPs (such as LPS) and 
DAMPs (such as HMGB1), whose excessive activation could 
stimulate macrophages, DCs, and neutrophils which play a vital 
role in adaptive immunity by contributing to sepsis (37, 38). 
Accumulating data showed that inhibition of TLR4 signaling by 
means of antibodies or soluble decoy receptors have proven to 
obtain a clinical benefit to sepsis (39). In this study, we found 
that the production of TNF-α, IL-1β, IL-6, IL-8, and IFN-β were 
downregulated in hS9-Fab03-treated LPS-stimulated human 
macrophages compared with control group, but slightly increased 
IL-10 production in an early time point. The downregulation of 
FigUre 7 | Western blot analysis for inhibition of lipopolysaccharide (lPs)-induced nF-κB, MaPKs, and irF-3 activation by hs9-Fab03. Cells were 
pretreated with 5 µg/ml of the hS9-Fab03 for 2 h and further incubated in presence or absence of LPS (1 µg/ml). After immunoblotting, the phosphorylation levels of 
p65, JNK1/2, p38, and IRF-3 were identified using phosphor-specific antibodies. Total p38 and GAPDH were used to ensure equal loading. L, LPS; A, hS9-Fab03. 
Data are shown as mean ± SD (n = 3, N.S., not significant, *p < 0.05, **p < 0.01, ***p < 0.001 compared to negative control).
11
Chu et al. Anti-hSiglec-9 Fab Inhibits TLR4 Responses
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 649
reFerences
1. Singer M. Biomarkers in sepsis. Curr Opin Pulm Med (2013) 19(3):305–9. 
doi:10.1097/MCP.0b013e32835f1b49 
2. Marik PE. Early management of severe sepsis: concepts and controversies. 
Chest (2014) 145:1407–18. doi:10.1378/chest.13-2104 
3. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment 
and functional disability among survivors of severe sepsis. JAMA (2010) 
304(16):1787–94. doi:10.1001/jama.2010.1553 
4. Canonical SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, et al.  
A network-based analysis of systemic inflammation in humans. Nature (2005) 
437:1032–7. doi:10.1038/nature03985 
5. Kawai T, Akira S. TLR signaling. Semin Immunol (2007) 19:24–32. 
doi:10.1016/j.smim.2006.12.004 
6. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms 
in sepsis. Nat Rev Immunol (2008) 8(10):776–87. doi:10.1038/ 
nri2402 
7. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. 
TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med (2007) 
13(11):1324–32. doi:10.1038/nm1663 
8. Cai B, Wang M, Zhu X, Xu J, Zheng W, Zhang Y, et al. The Fab fragment of a 
humanized anti-toll like receptor 4(TLR4) monoclonal antibody reduces the 
lipopolysaccharide response via TLR4 in mouse macrophages. Int J Mol Sci 
(2015) 16(10):25502–15. doi:10.3390/ijms161025502 
9. Wang M, Zheng W, Zhu X, Xu J, Cai B, Zhang Y, et al. A human anti-toll like 
receptor 4 Fab fragment inhibits lipopolysaccharide-induced pro-inflamma-
tory cytokines production in macrophages. PLoS One (2016) 11(1):e0146856. 
doi:10.1371/journal.pone.0146856 
10. Schnaar RL. Glycobiology simplified: diverse roles of glycan recogni-
tion in inflammation. J Leukoc Biol (2016) 99(6):825–38. doi:10.1189/
jlb.3RI0116-021R 
11. Büll C, Heise T, Adema GJ, Boltje TJ. Sialic acid mimetics to target the 
sialic acid-siglec axis. Trends Biochem Sci (2016) 41(6):519–31. doi:10.1016/ 
j.tibs.2016.03.007 
pro-inflammatory cytokines and the enhanced expression of 
IL-10 could be beneficial in preventing macrophage activation. It 
is well established that C/EBP and Sp1 are involved in activating 
the expression of IL-10 after stimulation by LPS (40). As shown 
in Figure 5F, pretreatment of hS9-Fab03 could enhance the IL-10 
expression after the LPS stimulation, which might contribute to 
the late tolerance in human macrophages. Siglecs could negatively 
regulate innate immunity by recruiting tyrosine phosphatase 
SHP-1 and -2 through their ITIMs (41). However, we did not 
detect the phosphorylation level of SHP-1 or -2 in the present 
study. Thus, the exact roles of hS9-Fab03 in enhanced production 
of IL-10 remain to be further investigated.
Human antibodies are broadly used in clinical diagnosis 
and treatment of diseases, which are produced by various DNA 
recombination technologies. Meanwhile, the phage display uti-
lizes the advantage of being inexpensive and efficient. Previously, 
we have constructed a fully human Fab phage library for Fab 
investigation, then smaller antibody fragments (Fabs or scFvs) 
could be comprised with phage display (9, 28). Considerable 
results have showed that these fragments preserve high efficiency 
in penetrating into the targeted tissue with high concentration 
and validity (42).
The exact mechanism of how hS9-Fab03 block TLR4 signaling 
transduction is still unknown. One possibility is that hS9-Fab03 
could directly bind to the Siglec-9 and induce the activation of 
SHP-1 or SHP-2, whose tyrosine phosphatase activity might 
inhibit the phosphorylation of downstream molecules of TLR4 
signaling pathway. In this case, the inhibition of LPS-induced 
IFN-β and TNF-α levels were increased in an antibody concen-
tration-dependent manner (Figures S1A,B in Supplementary 
Material), while Western blotting data showed that hS9-Fab03 
could suppress the phosphorylation of key molecules downstream 
of TLR4 pathway as shown in Figure 7. Additional studies should 
be performed to clarify the mechanism and exploit its biological 
effects in vivo.
In conclusion, we introduce the preparation and characteristics 
of a human anti-Siglec-9 antibody Fab fragment (hS9-Fab03), in 
this study, which could specifically bind to Siglec-9 with high affin-
ity. Pretreatment with hS9-Fab03 could suppress LPS-stimulated 
TLR4 signaling transduction and inhibit the production of 
pro-inflammatory cytokines in human macrophages. Our data 
suggest ligation of Siglec-9 with hS9-Fab03 might be a novel anti-
inflammatory therapeutic strategy for sepsis.
aUThOr cOnTriBUTiOns
MW, JZ, and XZ designed the experiments. SC, XZ, NY, WZ, BC, 
YW, and QS performed the experiments. SC, XZ, NY, WZ, FZ, 
and SN analyzed the data. ZY, XZ, and CW contributed reagents/
materials/analysis tools. SC and XZ wrote the paper.
FUnDing
This work was supported by the Grant (2013ZX09J13110-05B) 
from Chinese National Twelfth Five-year Plan Project, the 
Grant (BE2015651) from Social Development Project of Jiangsu 
Province, the Grant (BK20140094) from Jiangsu Province 
Science Foundation for Youths, the Grant (2016M592957) 
from the China Postdoctoral Science Foundation, the Grant 
(CNJ14L002) from Major Projects Foundation of General 
Logistics Department of PLA, and the Grant (14QNP041) from 
Youth Training Project of PLA.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2016.00649/full#supplementary-material.
FigUre s1 | The optimization of pre-incubation time and concentration 
of hs9-Fab03 and lipopolysaccharide (lPs). (a,B) PMA-stimulated 
THP-1-differentiated macrophages in 24 wells were pre-incubated with different 
concentrations of hS9-Fab03 for 2 h and then were stimulated with 1 µg/ml LPS. 
(c,D) The macrophages in 24 wells were pre-incubated with 5 µg/ml hS9-Fab03 
with different times then stimulated with 1 µg/ml LPS. (e,F) The macrophages in 
24 wells were pre-incubated with 5 µg/ml hS9-Fab03 for 2 h and then stimulated 
with different concentrations of LPS. The mRNA expression levels of IFN-β and 
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